OOIR: Observatory of International Research

Papers

(The H4-Index of Current Rheumatology Reports is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Kawasaki Disease: an Update	134
COVID-19 and Myositis: What We Know So Far	90
A Review of Complement Activation in SLE	66
Systemic Lupus Erythematosus in Children and Young People	59
New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO	56
Dissecting Fibroblast Heterogeneity in Health and Fibrotic Disease	54
Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences	54
T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update	50
Diagnostic Value of Muscle Ultrasound for Myopathies and Myositis	49
Epidemiology of Antiphospholipid Syndrome in the General Population	47
Update on Imaging-Based Measurement of Bone Mineral Density and Quality	44
Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides	42
Nanotechnological Strategies for Osteoarthritis Diagnosis, Monitoring, Clinical Management, and Regenerative Medicine: Recent Advances and Future Opportunities	40
From Psoriasis to Psoriatic Arthritis: Insights from Imaging on the Transition to Psoriatic Arthritis and Implications for Arthritis Prevention	36
The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency	36
New Criteria for Lupus	35
Current Understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and Its Distinction from Kawasaki Disease	32
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope	32
Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component	31
The Use of COVID-19 Vaccines in Patients with SLE	31
Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics	30
Fatty Acids and Oxylipins in Osteoarthritis and Rheumatoid Arthritis—a Complex Field with Significant Potential for Future Treatments	30
Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?	29
Current Epidemiology and Risk Factors for the Development of Hand Osteoarthritis	28
NETs in APS: Current Knowledge and Future Perspectives	28

Reactive Arthritis Update: Spotlight on New and Rare Infectious Agents Implicated as Pathogens	27
Work Disability in Axial Spondyloarthritis	26
The Role of Musculoskeletal Ultrasound in the Rheumatoid Arthritis Continuum	26